PBAC's latest decision on Mupirocin: Recommended (2019). Considered for Treatment of nasal colonisation of staphylococcus aureus infection (including MRSA) in Aboriginal and Torres Strait Islander persons.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2019
Submissions
1
2019 → 2019
Eligible population
Aboriginal and Torres Strait Islander persons with nasal colonisation of staphylococcus aureus (including MRSA).
Therapy area
Infectious disease
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
mupirocin 2% nasal ointment, 3g (Bactroban®)
Economic model
Cost-minimisation
ICER note
Not modelled — minor submission (new pack size of existing drug). Cost-minimisation approach only; no economic evaluation conducted.